Combo therapy lowers natriuretic peptide, study shows

But the study, PARALLAX, found no benefit in a six-minute walk test, researchers say

AusDoc brings you the latest news from the European Society of Cardiology Congress 2020.

Results of a trial of sacubitril and valsartan in patients with heart failure with preserved ejection fraction (HFpEF) show a reduction in N-terminal pro-b-type natriuretic peptide ( NT-proBNP), researchers report.

In the PARALLAX study, reported at the European Society of Cardiology’s virtual congress (ESC 2020) this week, patients with HFpEF were randomised to titrated dosing of